Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Oscar Vazquez

Orthopaedic Surgery Hackensack, NJ Medical Doctor

NPI 1063608875 CMS profile 275329

25 Prospect Ave, Hackensack, NJ 07601

Open in the dashboard

General payments

$87,396

350 records reported · program years 2019–2025

Research payments

$43,309

Paid to them · 23 records reported · program years 2019–2025

Ownership & investment interest

$870,757

5 holdings reported · through program year 2025

Research they led as principal investigator

$2,127 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Oscar Vazquez of Hackensack, NJ is reported in the CMS Open Payments database as having received $87,396 across 350 general payments and $43,309 in research payments paid to them. Separately, studies naming them as principal investigator received $2,127 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $870,757 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

16 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,698 27
2025 Research $13,510 3
2024 General $9,141 35
2024 Research $1,400 1
2023 General $20,571 65
2022 General $15,228 60
2022 Research $1,755 1
2021 General $22,421 59
2021 Research $2,402 2
2020 General $9,032 41
2020 Research $15,630 9
2019 General $4,305 63
2019 Research $8,612 7
2025 Ownership $720,757 3
2024 Ownership $75,000 1
2023 Ownership $75,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Oscar Vazquez
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Oscar Vazquez were reported at $6,698. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Oscar Vazquez Orthopaedic Surgery median Middle half National median
2019 $4,305 $644 $140–$2,844 $163
2020 $9,032 $312 $75–$1,860 $114
2021 $22,421 $520 $117–$2,495 $132
2022 $15,228 $598 $128–$2,731 $149
2023 $20,571 $461 $128–$2,264 $160
2024 $9,141 $497 $134–$2,475 $164
2025 $6,698 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $32,237 84 payments
  2. DePuy Synthes Products, Inc. $8,903 5 payments
  3. Anika Therapeutics, Inc. $7,184 7 payments
  4. Acumed LLC $6,795 24 payments
  5. Horizon Therapeutics plc $4,517 31 payments
  6. OSSIO Inc. $4,504 1 payment
  7. Abanza Inc. $3,194 3 payments
  8. SeaPearl Inc $3,026 22 payments
  9. DePuy Synthes Sales Inc. $2,855 45 payments
  10. Tenex Health Inc. $2,647 7 payments
  11. Other $11,535 121 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $45,604 32 payments
  2. Food and Beverage $16,734 275 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,914 2 payments
  4. Travel and Lodging $6,508 29 payments
  5. Honoraria $6,230 5 payments
  6. Education $2,139 4 payments
  7. Long term medical supply or device loan $181 1 payment
  8. Gift $67 1 payment
  9. Entertainment $19 1 payment
Products named General payments · program years 2019–2025
  1. Bone Anchors with Arthroscopic Delivery System $4,727 2 payments
  2. RevoMotion $3,862 2 payments
  3. WasherCap Mini Fixation system 4.5mm $3,194 3 payments
  4. WasherCap Fixation System 10mm $3,194 3 payments
  5. ACUMED Elbow $2,658 7 payments
  6. Coblation $2,465 3 payments
  7. ACUMED Elbow $2,432 10 payments
  8. Hipstruments $2,332 8 payments
  9. Q-FIX Hip $2,182 7 payments
  10. ACUMED Elbow $1,937 3 payments
  11. Other $38,166 315 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $17,788 13 payments
  2. Linvatec Corporation $14,910 4 payments
  3. Zimmer Biomet Holdings, Inc. $6,454 3 payments
  4. Smith+Nephew, Inc. $4,157 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

2,060

Median for Orthopedic Surgery: 203

Drug cost

$13,136

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 1,285 $4,262
Diclofenac Sodium Er Diclofenac Sodium Brand 173 $4,258
Celecoxib Generic 123 $1,795
Naproxen Generic 110 $978
Methylprednisolone Generic 97 $639
Cyclobenzaprine Hcl Generic 108 $418
Diclofenac Sodium Generic 14 $247
Tramadol Hcl Generic 69 $186
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 40 $170
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 15 $79

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$696,956

Of which drugs: $325,983

Medicare patients

743

Average age 75

Services billed

8,605

431 women, 312 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 30%
Chronic kidney disease 20%
Osteoporosis 19%
Cancer 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 291 551 $222,171
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 104 165 $83,145
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 520 2,221 $12,104

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record